Cas:1261956-44-8 4-bromo-2-ethoxy-N-propylbenzamide manufacturer & supplier

Chemical Name:4-bromo-2-ethoxy-N-propylbenzamide

CAS.NO:1261956-44-8

Synonyms:n-propyl 4-bromo-2-ethoxybenzamide

Molecular Formula:C₁₂H₁₆BrNO₂

Molecular Weight:286.16500

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:41.82000

Exact Mass:285.03600

LogP:3.56240

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like n-propyl 4-bromo-2-ethoxybenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-propyl 4-bromo-2-ethoxybenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-propyl 4-bromo-2-ethoxybenzamide Use and application,n-propyl 4-bromo-2-ethoxybenzamide technical grade,usp/ep/jp grade.

Related News: The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production. 1-((3-hydroxy-24,34-tetraoxidan-2-enyl)oxy)-4-(24-trioxidaneylidene)-13,34,44-pentaoxidane manufacturers Elliott made its intention for a C-suite overhaul clear in an open letter early July. The activist investor called on GSK to appoint a new board directors with biopharma and consumer health expertise to select the leaders for the two companies. Isoquinoline, 2-(2-chloroethyl)-1,2,3,4-tetrahydro- suppliers Injectable drug devices such as pens and cartridges accounted for 45% of the company’s sales last year, followed by insulin products with 16%. N-((4-methoxyphenyl)(phenyl)methyl)-4-nitrobenzenesulfonamide vendor & factory As for the expansion itself, Takeda will build a new 15,000-square-foot manufacturing facility at the site and expand an existing 14,000-square-feet of production space. Takeda has been knocking around the Thousand Oaks area since 1996, the Business Times said.,The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production.